Navigation Links
EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in,Preclinical Models

198, a novel tubulin binding agent, is also in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the integration of Miikana and its product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, produc
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
9. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
10. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
11. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
Post Your Comments:
(Date:3/30/2015)... 2015 TapImmune Inc . (OTCQB: TPIV), ... Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference at the ... York City on March 26.  TapImmune was ... , Chairman & CEO of TapImmune and Dr. ... due to parallel meeting sessions running behind schedule, Dr. Wilson was ...
(Date:3/30/2015)... DALLAS , March 30, 2015 ... on Global Colposcope Industry spread across 178 pages ... User PDF).  This is a professional ... overview analysis, the report introduces Colposcope basic information ... overview, policy analysis, and news analysis, etc. Key ...
(Date:3/30/2015)... Calif. , March 30, 2015  EP ... development to shareholders, EPGL has opened negotiations with ... Option to License their new ophthalmic technologies. As ... Communications, Inc. have co-developed new contact lens technologies, ... It is estimated by some industry experts that ...
Breaking Medicine Technology:Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" 2Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" 3Colposcope Market: 2015 - 2020 Global Manufacturers, Suppliers, Trend Analysis 2Colposcope Market: 2015 - 2020 Global Manufacturers, Suppliers, Trend Analysis 3Colposcope Market: 2015 - 2020 Global Manufacturers, Suppliers, Trend Analysis 4Colposcope Market: 2015 - 2020 Global Manufacturers, Suppliers, Trend Analysis 5CooperVision, Inc. Seeks Intermediary as EP Global Communications, Inc., Opens Negotiations at $1.1B 2CooperVision, Inc. Seeks Intermediary as EP Global Communications, Inc., Opens Negotiations at $1.1B 3
... , LAKE FOREST, Ill. , Aug. 2 Hospira, Inc. ... delivery company, today announced that the company will present at the Bank of ... , in Southampton. N.Y. , ... The presentation is scheduled to begin at 8:40 a.m. Eastern ...
... , Comprehensive study of outcome reporting taps ClinicalTrials.gov ... BOSTON ... for drug trials registered with ClinicalTrials.gov , those from industry-funded trials ... researchers at Children,s Hospital Boston. Publishing in the August 3 ...
Cached Medicine Technology:Hospira to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference Aug. 12 2Drug Trials Funded by Industry Are More Likely to Publish Favorable Results 2Drug Trials Funded by Industry Are More Likely to Publish Favorable Results 3Drug Trials Funded by Industry Are More Likely to Publish Favorable Results 4
(Date:3/30/2015)... This two day PT ... provide medical professionals with the information and techniques ... of fascia and its relationship to proper physiological ... PT CME course will provide extensive ... to identify and treat fascial restrictions. Techniques for ...
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 Foundations ... proud to announce the start of its 41st national ... author Jane McGonigal, and former Congressman Patrick J. Kennedy ... Conference being held in San Diego, CA, March ... Coronado. The national conference brings together leading experts specializing ...
(Date:3/30/2015)... The Consumer Attorneys Association of Los Angeles (CAALA) held ... for attorneys who passed the bar within the last five ... Southern California area to present about an array of challenges ... was on hand, not only as a sponsor, but to ... need to help in their evaluation, treatment, and med-legal reports. ...
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 KIND LED’s ... LED grow light products in 2015. The excellent value and ... them to take the pole position in the race for ... feature of the KIND LED suite of grow lights is ... most plant-friendly Photosynthetic Active Radiation (PAR) wavelengths that plants are ...
(Date:3/30/2015)... Healtheminds, a start-up focusing on providing ... innovative, easy to use and engaging online platform, is ... mental health related issues. The first in the series ... and other drugs. , Consumption and use of ... include the toxic effects of excessive intake or drug ...
Breaking Medicine News(10 mins):Health News:North American Seminars received New Jersey and California approval for Myofascial Release - From Surface to the Depths, a PT and OT Continuing Education Course. 2Health News:Foundations Recovery Network Kicks Off Its 41st National Conference Specializing in the Treatment of Substance Abuse and Behavioral Health 2Health News:Doctors on Liens Sponsors New Personal Injury Attorneys in Los Angeles 2Health News:Doctors on Liens Sponsors New Personal Injury Attorneys in Los Angeles 3Health News:Best LED Grow Lights of 2015 Are Being Led By KIND LED 2Health News:HealthEminds Launching Webinar on Drug Dependence 2
... being diagnosed with type 2 diabetes and now research shows ... for a heart attack and stroke. //Specifically, the research shows ... likely to suffer a heart attack and 30-times more likely ... ,"This means that huge numbers of people are going to ...
... breast cancer patients who receive radiation therapy after ... more likely to develop complications.// However, a new ... ,Researchers from the Fox Chase Cancer Center ... a mastectomy, breast reconstruction, and postoperative radiation between ...
... new tool to help acne patients. A new study highlights ... is important because this skin disease can lead to social ... ,Doctors from London recruited 41 adults with mild to ... of the pulsed-dye laser. The other 10 served as the ...
... A new study shows kidney patients have far more to ... Association-sponsored study shows people with chronic kidney disease are in ... most surprising finding was that this also applies to people ... ,Doctors have known patients in end-stage renal disease ...
... Babies will put almost anything in their mouths. But ... what they eat,// particularly if they have not tried ... particularly troublesome.But scientists say thousands of years ago toxins ... a high risk of food poisoning.,So it makes sense ...
... breastfeeding may help ward off obesity as children ... with limited long-term data available on breastfeeding and ... long-term studies aimed at clarifying the situation. In ... 18 years to see how breastfeeding impacts weight. ...
Cached Medicine News:
... and Proteomic users should inquire about ... Preparation capability for run-to-run replication. Compact ... accommodates 4x750 ml up to 4550xg ... throughput screening, research and patient specimen ...
Inquire...
... Hybridization Oven/Shaker rigidly controls the temperature ... of hybridization and washing steps. This ... of nucleic acids and proteins immobilized ... with radioactive and nonradioactive labeling systems ...
... GeneMachines HybStation is the first automated system ... automates all thermal and wash cycles for ... glass slides. A 12-position GeneMachines HybStation ... while the individual ports allow for independent ...
Medicine Products: